Skip to content

Medical emergency? What to do

New Brain Tumor Vaccine to Be Tested in Humans

3-RXPublished December 2, 20103 min read

Key points

  • For patients with low-grade gliomas, or slow growing brain tumors, a shot in the arm might soon lead to a new treatment therapy.
  • The trial is a bi-institutional pilot study, funded by the National Cancer Institute, and shared with the University of Pittsburgh (UP).
  • “If we can prevent the tumor from growing back or from transforming to a more malignant form, the hope is that we can cure more low-grade glioma patients,” Shaw said.
  • The vaccine was developed by UP’s Hideho Okada, M.D., Ph.D., the third side of this scientific triangle, and is based in part on Debinski’s discoveries.

For patients with low-grade gliomas, or slow growing brain tumors, a shot in the arm might soon lead to a new treatment therapy. A groundbreaking, first in humans vaccine will be tested in an early phase clinical trial that will soon begin at Wake Forest University Baptist Medical Center. Eighteen patients will be the first in the world to receive it.

“This study is looking at a very new form of treatment called a preventative brain tumor vaccine. The idea is to treat the low-grade glioma and to prevent it from growing back,” said Edward Shaw, M.D., a radiation oncologist. “In this early phase study, we are looking to see whether the patient develops an immune response against this kind of brain tumor, a necessary step for the vaccine to work.”

The trial is a bi-institutional pilot study, funded by the National Cancer Institute, and shared with the University of Pittsburgh (UP). Wake Forest Baptist and UP will enroll nine patients each. The vaccine will be administered to adult patients who have been diagnosed and had surgery for the removal of a low-grade brain tumor. They will receive the vaccine every three weeks for six months. A simple blood test will determine whether an immune response has developed.

Brain tumors are relatively uncommon when compared to other types of cancer, Shaw points out, but they are the most common cause of cancer death in children. Low-grade gliomas are the most common primary brain tumors and usually affect children and young adults in their 20s, 30s and 40s. Low-grade gliomas often recur after surgery and radiation and may progress to a higher grade, more aggressive brain tumor. When they do, there is no curative treatment.

“If we can prevent the tumor from growing back or from transforming to a more malignant form, the hope is that we can cure more low-grade glioma patients,” Shaw said.

The vaccine is the culmination of years of research and an interesting partnership that brings together three great scientific minds and their individual areas of expertise. Wake Forest Baptist has long been a leader, nationally and internationally, in the diagnosis and treatment of low-grade gliomas, and Shaw has led many of the research studies involving this type of tumor for the last 25 years. Shaw teamed up with Waldemar Debinski, Ph.D., director of the Brain Tumor Center of Excellence at Wake Forest Baptist, who discovered several of the glioma-associated antigens or molecules recognized by the immune system as foreign and targeted by the vaccine.

The vaccine was developed by UP’s Hideho Okada, M.D., Ph.D., the third side of this scientific triangle, and is based in part on Debinski’s discoveries.

Okada’s expertise lies in immunological therapy and gene therapy for brain tumors. Okada has a long track record of inventive research in the field of tumor vaccines. Shaw and Okada are co-principal investigators for the study. Okada was the first to identify and fully characterize cytotoxic T-lymphocyte (CTL) epitopes in glioma-associated antigens, enabling him to develop novel vaccines. CTLs are the warriors that the immune system uses to fight infections and cancer.

###

Source: Wake Forest University Baptist Medical Center

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underBrainCancer

Keep reading

Cancer

2 views are better than 1 in 3-D breast screening

One view 3D breast screening (tomosynthesis) means less radiation dose and about five seconds less compression, but a study from Yale University, New Haven, CT, found that obtaining both views is necessary to help…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.